AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.

DnD 2024 backgrounds grant characters stat increases, a starting feat, a range of proficiencies, and a clear backstory. This is a major shake-up to the original Dungeons and Dragons 5e rules, and it ...

We advise you to avoid simply saving the image previews you see below. These wallpaper previews are compressed and optimized for improved website performance. Instead, you should click the button ...

Zoom is a video conferencing app, geared towards business usage. It was founded in 2011 by Eric Yuan, and launched in January 2013. While gathering considerable popularity and coming to run profitably ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins and acquisitions, here’s a quick look at which stocks will be ...

Adding one of these travel photos as your Zoom background takes way less time than getting through customs. Here's how it's done. Make sure you have Zoom virtual backgrounds enabled on your Zoom ...

The Zoom call that followed was pivotal for the family. The professor explained that he believed Dr Wright was the first person to have suffered a rare reaction to the AstraZeneca Covid vaccine.

AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. CFO Aradhana Sarin outlined AstraZeneca ...

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...

Google Meets has similar layout options to Zoom. It allows breakout rooms and customized backgrounds. It has impressive integration options – it works with Google’s extensive library of apps ...

Genome en­gi­neer­ing busi­ness Syn­thego will have ac­cess to As­traZeneca’s CRISPR gene edit­ing en­zyme in its sec­ond li­cens­ing agree­ment in the past year.